Dapagliflozin modulates diabetic kidney disease through indirect transcriptional regulation rather than direct transcriptional reversal.
文献摘要
Background Diabetic kidney disease (DKD) is the leading cause of kidney failure worldwide. While sodium-glucose co-transporter 2 inhibitors (SGLT2i) confer remarkable renoprotection, the molecular mechanisms underlying their efficacy remain incompletely understood. Methods We performed an integrative cross-species transcriptomic analysis comparing dapagliflozin-modulated signatures in diabetic mice with human DKD pathophysiology. Public RNA-sequencing datasets were analyzed: GSE142025 (human kidney biopsies: advanced DKD n = 21, early DKD n = 6, controls n = 9) and GSE228727 (diabetic db/db mice ± dapagliflozin). Results Advanced human DKD exhibited 2145 dysregulated genes (False Discovery Rate [FDR] Conclusion SGLT2 inhibitors do not reverse disease transcriptional programs but operate through indirect modulation of a focused gene signature largely independent of primary disease drivers. This signature provides prioritized candidates for mechanistic investigation and biomarker development in DKD.